Four decades. Billions spent.
Called "undruggable."

KRAS is mutated in 25% of all human cancers — pancreatic, lung, colorectal. For 40 years it was considered undruggable because the protein has no obvious binding pocket. Traditional drug discovery requires a cavity to lock into. LoNC doesn't require a cavity — it finds the physics of how molecules interact with the surface. It found the Switch-II pocket that enabled Sotorasib, the first approved KRAS inhibitor, in minutes.

Keytruda. Oral.
No more infusion chairs.

PD-1/PD-L1 checkpoint inhibitors (Keytruda, Opdivo) are among the most transformative cancer drugs ever developed — and every patient receives them intravenously. The same LoNC platform that discovered the checkpoint mechanism identified small molecule candidates for oral checkpoint inhibition. The same efficacy. A pill instead of an IV.

One platform.
Every cancer mechanism.

Not one cancer.
The whole landscape.